ATE157005T1 - Verwendung von sertindol zur behandlung von schizophrenie - Google Patents

Verwendung von sertindol zur behandlung von schizophrenie

Info

Publication number
ATE157005T1
ATE157005T1 AT90610022T AT90610022T ATE157005T1 AT E157005 T1 ATE157005 T1 AT E157005T1 AT 90610022 T AT90610022 T AT 90610022T AT 90610022 T AT90610022 T AT 90610022T AT E157005 T1 ATE157005 T1 AT E157005T1
Authority
AT
Austria
Prior art keywords
sertindole
treat schizophrenia
dopamine neurones
neurones
imidazolidinon
Prior art date
Application number
AT90610022T
Other languages
German (de)
English (en)
Inventor
Jens Kristian Perregaard
Torben Skarsfeldt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10654774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE157005(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE157005T1 publication Critical patent/ATE157005T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
AT90610022T 1989-04-11 1990-03-30 Verwendung von sertindol zur behandlung von schizophrenie ATE157005T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898908085A GB8908085D0 (en) 1989-04-11 1989-04-11 New therapeutic use

Publications (1)

Publication Number Publication Date
ATE157005T1 true ATE157005T1 (de) 1997-09-15

Family

ID=10654774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90610022T ATE157005T1 (de) 1989-04-11 1990-03-30 Verwendung von sertindol zur behandlung von schizophrenie

Country Status (17)

Country Link
US (1) US5112838A (enExample)
EP (1) EP0392959B1 (enExample)
JP (1) JP2775191B2 (enExample)
KR (1) KR920008703B1 (enExample)
AT (1) ATE157005T1 (enExample)
AU (1) AU621735B2 (enExample)
CA (1) CA2014208C (enExample)
CY (1) CY2082B1 (enExample)
DE (2) DE19875011I2 (enExample)
DK (1) DK0392959T3 (enExample)
GB (1) GB8908085D0 (enExample)
IE (1) IE81157B1 (enExample)
IL (1) IL94021A (enExample)
NL (1) NL980008I1 (enExample)
NZ (2) NZ243765A (enExample)
SG (1) SG48234A1 (enExample)
ZA (1) ZA902785B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
DK8492D0 (da) * 1992-01-23 1992-01-23 Lundbeck & Co As H Behandling af psykoser
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
DK1026950T3 (da) * 1997-10-27 2006-06-26 Univ California Behandling af skizofreni med ampakiner og neuroleptika
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
DE60239634D1 (de) * 2001-12-10 2011-05-12 Novartis Ag Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
MXPA04009365A (es) * 2002-03-27 2005-01-25 Lundbeck & Co As H Metodo para la manufactura de sertindol.
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
EP2041304B1 (en) * 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2008106144A2 (en) * 2007-02-28 2008-09-04 Nupathe Inc. Implants for the treatment of psychiatric states
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Also Published As

Publication number Publication date
EP0392959A3 (en) 1992-05-06
IE901051L (en) 1990-10-11
IE81157B1 (en) 2000-05-03
AU621735B2 (en) 1992-03-19
NZ243765A (en) 1997-09-22
JP2775191B2 (ja) 1998-07-16
US5112838A (en) 1992-05-12
DK0392959T3 (da) 1999-03-29
AU5303790A (en) 1990-10-18
EP0392959B1 (en) 1997-08-20
CA2014208C (en) 1996-03-19
KR900015730A (ko) 1990-11-10
GB8908085D0 (en) 1989-05-24
ZA902785B (en) 1991-06-26
DE69031290D1 (de) 1997-09-25
CY2082B1 (en) 1998-10-16
IL94021A (en) 1994-01-25
CA2014208A1 (en) 1990-10-11
JPH02290872A (ja) 1990-11-30
NL980008I1 (nl) 1998-05-06
DE19875011I2 (de) 2004-07-01
DE69031290T2 (de) 1998-01-02
NZ233179A (en) 1996-12-20
IL94021A0 (enExample) 1991-01-31
HK1002825A1 (en) 1998-09-18
KR920008703B1 (ko) 1992-10-08
EP0392959A2 (en) 1990-10-17
SG48234A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
ATE157005T1 (de) Verwendung von sertindol zur behandlung von schizophrenie
SE8804629D0 (sv) New therapeutically active compounds
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE142107T1 (de) Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
NO173998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
DE3780940D1 (de) Verwendung von ketonderivaten zur behandlung von depressionen.
NO167204C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diacylderivater av 4-(trialkylbenzyl)-piperazinylforbindelser.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
NO167456C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 7-(3-amino-1-pyrrolidinyl)-8-brom-1-syklopropyl-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
NO170852C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DE69022206D1 (de) Aldosereduktasehemmer enthaltende Zubereitungen zur Behandlung von Geschwüren.
ATE286728T1 (de) Verwendung von homocysteinderivaten zur behandlung von bakteriellen infektionen
DE60312656D1 (de) Arzneimittel zur behandlung von störungen des zirkadianen rhythmus